

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
09 March 2023 (09.03.2023)



(10) International Publication Number
WO 2023/031359 A1

(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 31/7125 (2006.01)

A61K 31/713 (2006.01) A61K 31/712 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2022/074386

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:

01 September 2022 (01.09.2022)

Published:

— with international search report (Art. 21(3))

(25) Filing Language:

English

— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(26) Publication Language:

English

(30) Priority Data:

21194654.6 02 September 2021 (02.09.2021) EP

(71) Applicant: **SILENCE THERAPEUTICS GMBH**
[DE/DE]; Robert-Rössle-Strasse, 13125 Berlin (DE).

(72) Inventors: **DAMES, Sibylle**; c/o Silence Therapeutics
GmbH, Robert-Rössle-Strasse, 13125 Berlin (DE). **MOR-**
RISON, Eliot; c/o Silence Therapeutics GmbH, Robert-
Rössle-Strasse, 13125 Berlin (DE). **AUMILLER, Vere-**
na; c/o Silence Therapeutics GmbH, Robert-Rössle-Strasse,
13125 Berlin (DE). **JOHANSEN, Timo**; c/o Silence
Therapeutics GmbH, Robert-Rössle-Strasse, 13125 Berlin
(DE). **RATHJEN, Stefan**; c/o Silence Therapeutics GmbH,
Robert-Rössle-Strasse, 13125 Berlin (DE). **SCHUBERT,**
Steffen; c/o Silence Therapeutics GmbH, Robert-Rössle-
Strasse, 13125 Berlin (DE).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Coun-
terslip, Bristol Bristol BS1 6BX (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF COMPLEMENT FACTOR B (CFB) IN A CELL

(57) Abstract: The invention relates to nucleic acid products that interfere with complement factor B (CFB) gene expression or inhibit its expression. The nucleic acids are preferably for use in the prophylaxis or treatment of complement associated diseases, disorders or syndromes, particularly C3 glomerulopathy (C3G), paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), lupus nephritis, IgA nephropathy (IgA N), myasthenia gravis (MG), and primary membranous nephropathy.

WO 2023/031359 A1